Epigral Limited — Investor Meet, 13-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Epigral's Q2 FY26 revenue declined 4% to Rs 589 Cr, with PAT at Rs 51 Cr, mainly due to lower realizations in CPVC, hydrogen peroxide, and caustic soda. H1 EBITDA margin stood at 25%. Management anticipates H2 performance to improve with demand recovery and higher plant utilization (currently 78%). Capacity doubling for CPVC and Epichlorohydrin, along with new power plants, are on track. Future CAPEX plans focus on import substitution and high-growth segments beyond FY2028. The company maintains a strong financial position with Net Debt/EBITDA at 0.8x, expressing confidence in long-term growth despite short-term market volatility.